Peptides 101: A Beginner's Clinical Guide

Peptides are short chains of amino acids, typically 2 to about 50 residues long, with molecular weights usually between 500 and 5,000 daltons.12 Your body already runs on them — insulin, oxytocin, glucagon and many hormones are peptides — and in medicine more than 80 peptide drugs are already FDA-approved and globally marketed, with 150-200+ more in active clinical development.1 The single most important thing a beginner must understand is that the category spans a vast spectrum of evidence, from blockbuster medicines to unproven gray-market compounds.

This article is informational and editorial content for educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Most peptides discussed are not FDA-approved drugs; many are sold illegally as "research chemicals not for human use." Where doses or routes appear they are reported strictly as seen in published literature or approved labeling, never as recommendations. Consult a qualified, licensed clinician before making any health decision.

What exactly is a peptide?

A peptide is a short chain of amino acids joined by peptide bonds — covalent links formed between the carboxyl group of one amino acid and the amino group of the next.3 Amino acids are the building blocks; string a few dozen together and you have a peptide; string many more and the chain folds into a protein. The line between "peptide" and "protein" is a matter of convention rather than a hard biological boundary.

Insulin — a 51-amino-acid peptide hormone — was the first peptide drug, first produced in a lab and used to treat type 1 diabetes beginning in the early 1920s.4 Because peptides sit between small-molecule drugs (like ibuprofen) and large biologics (like monoclonal antibodies), they can bind a target receptor with the high specificity and potency of a large biologic while being smaller and often less immunogenic.1 Their main drawback is fragility: most peptides are broken down rapidly by digestive enzymes and have short half-lives, which is why so many are injected rather than swallowed.1

Peptides are fundamentally signaling molecules: they bind target proteins — usually cell-surface receptors — and switch biological processes on or off, from appetite and blood sugar to hormone release and tissue repair.1 A GLP-1 peptide, for example, binds the GLP-1 receptor in the brain and gut to reduce appetite and slow gastric emptying.5 This receptor-targeted mechanism is the source of both their precision and the integrative-medicine appeal of "working with the body's own signaling" — but a plausible mechanism is a hypothesis, not a result. The only way to know whether a peptide helps a human is a human trial.

How do peptides differ from drugs, hormones, and supplements?

One of the biggest sources of confusion is what regulatory and conceptual bucket a peptide falls into — and the honest answer is that it depends entirely on the specific peptide.

Peptides vs. "drugs." A peptide approved by the FDA, with a prescribing label, is a drug. Semaglutide (Wegovy/Ozempic), tirzepatide (Zepbound/Mounjaro), teriparatide (Forteo), bremelanotide (Vyleesi) and tesamorelin (Egrifta) are peptide drugs in every legal and clinical sense.19 The peptide-vs-drug distinction is therefore false for these agents — they are drugs that happen to be peptides. The distinction only becomes meaningful for the unapproved peptides, which are not legally drugs because they have never been through the approval process.

Peptides vs. hormones. Many hormones are peptides — insulin, glucagon, oxytocin, growth hormone and parathyroid hormone are all peptide hormones.24 "Peptide vs. hormone" is a category error: a hormone is defined by its function (a signaling molecule released into circulation to act on distant tissues), while a peptide is defined by its chemistry (a short amino-acid chain). Some peptides are hormones; some hormones (estrogen, testosterone) are steroids, not peptides.

Peptides vs. supplements. This is where consumers get hurt. Some products genuinely qualify as supplements — collagen peptides and creatine peptides, for instance.4 But the injectable "research peptides" at the center of the wellness boom — BPC-157, TB-500, the growth-hormone-releasing peptides — are not legal dietary supplements. Products marketed for human therapeutic use without FDA approval are, in the agency's own framing, unapproved new drugs that are misbranded or adulterated.13 Calling an injectable peptide a "supplement" does not make it one. Before you treat any peptide as a "supplement," "drug," or "hormone," identify the specific molecule and its specific regulatory status — the label on the box is marketing, not law.

What are the major classes of peptides?

The peptide universe is most usefully organized by what the peptide does. Many widely sold peptides cluster in the tissue-repair, longevity, and growth-hormone "optimization" categories — exactly the categories where the evidence is weakest. The marketing intensity of a peptide is, unfortunately, often inversely correlated with the strength of its human evidence.

This table is a map, not a verdict; individual peptides vary, so always check the specific molecule against its own evidence grade.

What does the evidence actually support?

This is the heart of the guide. The evidence-first rule is simple: separate human randomized trials from animal/test-tube findings from anecdote, and grade every claim accordingly. A mechanism in a mouse is not a result in a person. Throughout this site we use a four-tier scale — Grade A (human RCTs and/or meta-analyses), Grade B (human evidence below RCT level — cohort, observational, small or open-label), Grade C (preclinical only — animal and/or in-vitro, no qualifying human efficacy data), and Grade D (anecdotal, expert-opinion, mechanism-only or marketing claim).

What the strong evidence supports (Grade A). A handful of peptide medicines are among the best-evidenced drugs of the last decade. In the 68-week STEP 1 randomized controlled trial of 1,961 adults, once-weekly semaglutide 2.4 mg produced mean weight loss of 14.9% versus 2.4% with placebo.5 In the Phase 3 SURMOUNT-1 trial (2,539 adults), tirzepatide produced dose-dependent mean weight reductions of up to 22.5% versus 2.4% with placebo.6 In the landmark Fracture Prevention Trial, daily teriparatide cut the risk of new vertebral fractures by roughly 65% in postmenopausal women.8 Two identical Phase 3 RCTs of bremelanotide (RECONNECT; 1,267 women) improved sexual desire and reduced desire-related distress, leading to FDA approval as Vyleesi.7 And tesamorelin, a GHRH analog, reduced HIV-associated visceral fat by more than 15% in two 26-week RCTs and was reformulated as weekly EGRIFTA WR in 2025.910 You can track the underlying data for many of these agents at ClinicalTrials.gov, the U.S. registry of clinical studies.

What the evidence does NOT yet support (Grade C-D). The peptides most heavily promoted in the wellness, biohacking and gym communities are, with few exceptions, the ones with the weakest human evidence. BPC-157 is the marquee example: its tissue-repair reputation rests on an extensive, reasonably consistent animal literature, but a 2025 review and the trial registry confirm no completed human randomized controlled trials — the only human data are tiny uncontrolled pilots.11 TB-500 (thymosin β4), KPV, MOTS-c and most "regenerative" and "longevity" peptides occupy the same tier: interesting mechanisms, animal or test-tube data, no qualifying human efficacy trials. Growth-hormone "optimization" peptides reliably raise GH/IGF-1 levels, but raising a lab value is not the same as a proven clinical benefit. The functional-medicine instinct to "support the body's own healing" is not unreasonable as a framing, but it cannot manufacture evidence that does not exist. When the human data are absent, the honest statement is "we don't know if this works in people," not "it works naturally."

What are the safety and gray-market ground rules?

Even the well-studied peptides are not benign: GLP-1 drugs commonly cause nausea, vomiting and diarrhea and carry labeled warnings; teriparatide carries an osteosarcoma black-box warning; bremelanotide commonly causes nausea, flushing and headache.78 For BPC-157, TB-500 and most gray-market peptides there is no controlled human safety data at all — no established safe dose, no characterized interactions, no long-term outcomes.11 Several tissue-repair and growth-promoting peptides are pro-angiogenic or pro-growth, raising at least a theoretical concern for anyone with a personal or family history of cancer.

Often the gray-market product itself is the biggest hazard. A 2024 forensic study in the Journal of Medical Internet Research purchased semaglutide from online sellers requiring no prescription and found, against a labeled "99% purity" claim, measured purity of just 7.7%-14.4%, endotoxin detectable in every sample, and packaging non-compliant on most quality criteria — classifying all products as "probable substandard and falsified."12 The "99% pure" claim is an HPLC peptide-vs-peptide measure that says nothing about endotoxins, metals, or sterility. Injectable peptides must be sterile; gray-market lyophilized powders are generally not sterilized by validated methods and can carry endotoxin loads that trigger systemic inflammation, with consequences ranging from local abscess to sepsis.13 Pregnancy and breastfeeding, a history of cancer, concurrent prescription medication, and competitive-athlete status are all reasons for special caution or abstention.

What is the U.S. legal and WADA status in 2026?

Peptide legality is specific to the molecule and the supply channel, and it is changing fast. A peptide is legally a medicine only if the FDA has approved it; approved peptide drugs are available by prescription, while everything else is a compounded product, a dietary-ingredient claim, or — most commonly for gym/wellness peptides — an illegally marketed unapproved drug sold under a "research use only" disclaimer that is legal cover for the seller, not a safety designation.13

Compounding pharmacies (regulated under Sections 503A and 503B) can prepare medications from bulk substances only in defined circumstances, and a peptide can be lawfully compounded only if it is FDA-approved, the subject of a USP monograph, or on the 503A bulk drug substances list; substances flagged as posing potential safety concerns were placed in "Category 2," effectively barring compounding.14 In April 2026 the FDA removed 12 peptides from Category 2 — including BPC-157, TB-500, GHK-Cu (injectable), KPV, MOTS-c, Semax, Epitalon and Melanotan II — but removal from Category 2 does NOT make a peptide legal to compound or use; it merely clears the way for the Pharmacy Compounding Advisory Committee (PCAC) to evaluate whether a substance should be added to the 503A bulks list.1416 The PCAC is scheduled to meet July 23-24, 2026 to evaluate seven peptides; it is advisory only, and even a favorable recommendation would require subsequent FDA rulemaking, with the products still prescription-only and not FDA-approved.1513 "Removed from Category 2" is routinely misrepresented by sellers as "FDA-cleared" — it is not.

For any athlete subject to anti-doping rules the situation is stark. The WADA 2026 Prohibited List bans the major performance peptides at all times: the S2 category covers peptide hormones, growth factors and secretagogues (CJC-1295, sermorelin, tesamorelin, ipamorelin, MK-677, and TB-500/thymosin β4), while the S0 "non-approved substances" category captures BPC-157 and other research peptides.17 Detection windows for many peptides extend well beyond their short plasma half-lives. If you compete under WADA rules, assume any peptide is banned until you have verified otherwise with the official list.

Bottom line. Peptides are a legitimately exciting drug class with a handful of transformative, RCT-proven medicines — and a much larger fringe of heavily marketed compounds whose human evidence is thin to nonexistent. The beginner's most valuable skill is not memorizing peptides but calibrating claims: separate human RCTs from animal data from anecdote, identify the specific molecule and its regulatory status, and remember that the louder and more universal the claim, the weaker the evidence usually is. Regulatory facts here are current as of June 2026; the July 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.